Previous 10 | Next 10 |
908 Devices Inc. (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022. Company manag...
908 Devices went public in December 2020, raising $130 million in gross proceeds in a U.S. IPO. The firm sells mass spectrometry devices in handheld and desktop versions to businesses and government agencies. MASS's revenue outlook can be 'lumpy' from quarter to quarter and it has...
Full year 2021 revenue growth of at least 54% compared to 2020 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced preliminary, unaudited revenue for the fourth quarter and...
908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL ™ cell culture media analyzer. GSK will now have a total of five ...
Premier CBRNE training facility uses 908 Devices MX908 portable mass spec devices for trace detection of hazardous chemicals 908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announc...
908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the pricing of a public offering of shares of its common stock, with 3,150,000 shares being offered by the Company at a public offer...
908 Devices (NASDAQ:MASS) trades 2.4% down after hours on launching 2.75M in stock offering; underwriters granted 30-day option to purchase up to an additional 412.5K shares. Offer size, terms have not yet been disclosed. Net proceeds along with cash and equivalents to be used for g...
908 Devices Inc. (NASDAQ: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced the launch of a public offering of shares of its common stock, with 2,750,000 shares being offered by the Company pursuant to a regi...
908 Devices Inc. (MASS) Q3 2021 Earnings Conference Call November 04, 2021 08:30 AM ET Company Participants Kelly Gura - Investor Relations Kevin Knopp - Chief Executive Officer and Co-Founder Joe Griffith - Chief Financial Officer Conference Call Participants Puneet Souda - SVB Leerink Max M...
Image source: The Motley Fool. 908 Devices Inc. (NASDAQ: MASS) Q3 2021 Earnings Call Nov 04, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: 908 Devices Inc. (MASS) Q3 2021 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately. Ms....
Updated technology enables first responders to identify and quantify approximately 5,000 substances in mere seconds for a swift and definitive response 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an ...
2024-06-01 11:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...